Cardiomyocyte-specific Overexpression of Syndecan-4 in Mice Results in Activation of Calcineurin-NFAT Signalling and Exacerbated Cardiac Hypertrophy
Overview
Authors
Affiliations
Background: Cardiomyocyte hypertrophy is a hallmark of cardiac dysfunction in patients with aortic stenosis (AS), and can be triggered by left ventricular (LV) pressure overload in mice by aortic banding (AB). Syndecan-4 is a transmembrane heparan sulphate proteoglycan which is found increased in the myocardium of AS patients and AB mice. The role of syndecan-4 in cardiomyocyte hypertrophy is not well understood.
Purpose Of The Study: We developed mice with cardiomyocyte-specific overexpression of syndecan-4 (Sdc4-Tg) and subjected these to AB to examine the role of syndecan-4 in hypertrophy and activation of the pro-hypertrophic calcineurin-NFAT signalling pathway.
Methods And Results: Sdc4-Tg mice showed exacerbated cardiac remodelling upon AB compared to wild type (WT). At 2-6 weeks post-AB, Sdc4-Tg and WT mice showed similar hypertrophic growth, while at 20 weeks post-AB, exacerbated hypertrophy and dysfunction were evident in Sdc4-Tg mice. After cross-breeding of Sdc4-Tg mice with NFAT-luciferase reporter mice, we found increased NFAT activation in Sdc4-Tg hearts after AB. Immunoprecipitation showed that calcineurin bound to syndecan-4 in Sdc4-Tg hearts. Isolated cardiomyocytes from Sdc4-Tg mice showed alterations in Ca fluxes, suggesting that syndecan-4 regulated Ca levels, and thereby, activating the syndecan-4-calcineurin complex resulting in NFAT activation and hypertrophic growth. Similarly, primary cardiomyocyte cultures from neonatal rats showed increased calcineurin-NFAT-dependent hypertrophic growth upon viral Sdc4 overexpression.
Conclusion: Our study of mice with cardiomyocyte-specific overexpression of Sdc4 have revealed that syndecan-4 is important for activation of the Ca-dependent calcineurin-NFAT signalling pathway, hypertrophic remodelling and dysfunction in cardiomyocytes in response to pressure overload.
Unlocking the therapeutic potential of the NFAT pathway in kidney diseases.
Shreya S, Dagar N, Gaikwad A Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 40088333 DOI: 10.1007/s00210-025-04033-x.
Zhang Z, Lian T, Cheng Q, Zhu M, Lv J Curr Med Sci. 2024; 44(6):1071-1080.
PMID: 39672998 DOI: 10.1007/s11596-024-2952-5.
Exploring Syndecan-4 and MLP and Their Interaction in Primary Cardiomyocytes and H9c2 Cells.
Stole T, Lunde M, Gehmlich K, Christensen G, Louch W, Carlson C Cells. 2024; 13(11.
PMID: 38891079 PMC: 11172336. DOI: 10.3390/cells13110947.
Yi C, Huang D, Yu H, Gu J, Liang H, Ren M Foods. 2023; 12(18).
PMID: 37761194 PMC: 10529141. DOI: 10.3390/foods12183485.
Cardiovascular changes in the NZB/W F1 mouse model of lupus nephritis.
Bohme R, Daniel C, Ferrazzi F, Angeloni M, Ekici A, Winkler T Front Cardiovasc Med. 2023; 10:1182193.
PMID: 37554366 PMC: 10405627. DOI: 10.3389/fcvm.2023.1182193.